Loading…
Loading…
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Institutional and Insider Ownership 79.7% of Prelude Therapeutics
NEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, announced today that Dr. Deborah Rathjen, Executive Chair, will be attending the following industry conferences:
NEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Shadow Lake Group Inc. and its affiliate SLG Europe BV (“SLG”) as Business Development advisor.
NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhance the delivery of biologics across the blood-brain barrier (“BBB”) for the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that the Japanese Patent Office (“JPO”) issued Japanese Patent No. 2019-189551 Notice of Allowance for the Company's xB3-IDS fusion proteins.
NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited quarterly financial statements and management's discussion and analysis for the period ended May 31, 2021. All are available under the Company's profile on SEDAR and on the Company's website at www.bioasis.us/investors/.
NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,367,606 common shares effective June 30, 2020 at a price of $0.38 per share to directors and officers of the Company and an investor relations consultant. All of the options expire five years from the date of the grant and are governed by the terms of the company's stock option plan. The options are being issued as part of annual remuneration in lieu of cash compensation as the company prioritizes investment in partnership enhancing R&D.
Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) said results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor were successful in a preclinical rodent model of multiple sclerosis. Connecticut-based Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 platform technology for the delivery of therapeutics across the blood-brain barrier (BBB), as well as the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.
NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhance the delivery of biologics across the blood-brain barrier (“BBB”) for the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced positive results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis.
No recent filings indexed.